Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13589374 | 1.00 | TK1 (0.65) | TK1POLB | |
| SCHEMBL9483871 | 1.00 | TK1 (0.65) | TK1POLB | |
| SCHEMBL51992 | 1.00 | TK1 (0.65) | TK1POLB | |
| SCHEMBL16480963 | 1.00 | TK1 (0.65) | TK1POLB | |
| SCHEMBL16693741 | 1.00 | TK1 (0.65) | TK1POLB | |
| SCHEMBL24233253 | 1.00 | TK1 (0.65) | TK1POLB | |
| SCHEMBL6063494 | 0.99 | TK1 (0.63) | TK1POLB | |
| SCHEMBL5293362 | 0.95 | TK1 (0.60) | TK1POLB | |
| SCHEMBL655193 | 0.90 | TK1 (0.67) | TK1POLB | |
| Doxribtimine SCHEMBL9222730 | 0.89 | TK1 (0.71) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339402-B1 | AZAPHENANTHRIDONE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | EISAI INC (US) | 2010-08-25 | — | — | EP | claimed |
| US-20060003987-A1 | Compounds and their uses | GUILFORD PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | US | claimed |
| WO-1996039183-A9 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF EFFECTOR MOLECULES | — | 1997-01-30 | — | — | WO | claimed |
| WO-1996039183-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF EFFECTOR MOLECULES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1996-12-12 | — | — | WO | claimed |
| US-4093716-A | Compositions containing 5-amino-5-deoxythymidine and pharmaceutically acceptable salts thereof | RESEARCH CORPORATION (US) | 1978-06-06 | — | — | US | claimed |
| JP-1250393-A | — | — | None | — | — | JP | disclosed |
| US-12054768-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4123031-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | The Regents of The University of California (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3283638-B1 | METHODS FOR DETECTING AGGLUTINATION AND USE OF KITS IN PRACTICING THE SAME | UNIV CALIFORNIA (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210403978-A1 | METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-30 | — | — | US | disclosed |
| US-11149296-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-19 | — | — | US | disclosed |
| US-10774105-B2 | Phosphoroamidate esters, and use and synthesis thereof | STRATOS GENOMICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| WO-1988008419-A1 | OLIGOBIPYRIDINE LIGANDS, PROCESS FOR OBTAINING THEM AND APPLICATION AS COMPLEXING AGENTS | COMPAGNIE ORIS INDUSTRIE S.A. (FR) | 1988-11-03 | — | — | WO | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| US-4730001-A | HERPES VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 1988-03-08 | — | — | US | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
| US-4710492-A | MURINE LEUKEMIA, SARCOMA AND AIDS VIRUSES | YALE UNIVERSITY (US) | 1987-12-01 | — | — | US | disclosed |
| US-4128639-A | ANTICANCER | RESEARCH CORPORATION (US) | 1978-12-05 | — | — | US | disclosed |
| US-4093716-A | Compositions containing 5-amino-5-deoxythymidine and pharmaceutically acceptable salts thereof | RESEARCH CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
| US-4093716-A | Compositions containing 5-amino-5-deoxythymidine and pharmaceutically acceptable salts thereof | RESEARCH CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003987-A1 | Compounds and their uses | PARP1, PARP2, PARP3 | TK1 1899/4885POLB 112/4885 |
| US-10774105-B2 | Phosphoroamidate esters, and use and synthesis thereof | PNP, RNGTT, TYMP | TK1 71/4885POLB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.